TARS FY 2020 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$246,000

Operating Income

-$27M

Net Income

-$27M

EPS (Diluted)

$-1.32

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$22M

Stock-Based Comp.

$839,000

Balance Sheet

Total Assets

$172M

Total Liabilities

$6M

Stockholders' Equity

$166M

Cash & Equivalents

$168M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$246,000	-$74,000	-232.4%
Operating Income	-$27M	-$4M	-527.8%
Net Income	-$27M	-$5M	-474.1%